Literature DB >> 9372238

Inactivation of MyoD-mediated expression of p21 in tumor cell lines.

A D Otten1, E J Firpo, A N Gerber, L L Brody, J M Roberts, S J Tapscott.   

Abstract

The basic helix-loop-helix protein MyoD induces muscle structural gene expression and cell cycle withdrawal in many nontransformed cell lines. We show that MyoD activation of transcription of the cyclin-dependent kinase inhibitor p21 does not require synthesis of an intermediary protein. In most of the rhabdomyosarcoma and other solid tumor cell lines that we analyzed, p21 levels were abnormally low and correlated with the combined inactivity of MyoD and p53, two known transcriptional activators of p21. Loss of MyoD activation of p21 transcription correlated with the failure to arrest in G1, and expression of p21 caused accumulation of cells in G1, further supporting a role for p21 in MyoD-induced cell cycle arrest. Finally, different tumor types have inactivated distinct factors necessary for p21 expression, because p21 expression was reconstituted in hybrid cell lines. We propose that p21 integrates growth-inhibitory signals from independent p53 and basic helix-loop-helix pathways, and that in the majority of tumor cell lines, both pathways are abrogated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9372238

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  21 in total

1.  CDK inhibitors for muscle stem cell differentiation and self-renewal.

Authors:  Amrudha Mohan; Atsushi Asakura
Journal:  J Phys Fit Sports Med       Date:  2017

2.  Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state.

Authors:  Min-Hyung Lee; Mathivanan Jothi; Andrei V Gudkov; Asoke K Mal
Journal:  Cancer Res       Date:  2011-04-14       Impact factor: 12.701

3.  CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells.

Authors:  Priya Londhe; Bo Zhu; Jinu Abraham; Charles Keller; Judith Davie
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.396

4.  Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells.

Authors:  P L Puri; Z Wu; P Zhang; L D Wood; K S Bhakta; J Han; J R Feramisco; M Karin; J Y Wang
Journal:  Genes Dev       Date:  2000-03-01       Impact factor: 11.361

5.  MyoD is a tumor suppressor gene in medulloblastoma.

Authors:  Joyoti Dey; Adrian M Dubuc; Kyle D Pedro; Derek Thirstrup; Brig Mecham; Paul A Northcott; Xiaochong Wu; David Shih; Stephen J Tapscott; Michael LeBlanc; Michael D Taylor; James M Olson
Journal:  Cancer Res       Date:  2013-10-03       Impact factor: 12.701

6.  MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state.

Authors:  Zhihong Yang; Kyle L MacQuarrie; Erwin Analau; Ashlee E Tyler; F Jeffery Dilworth; Yi Cao; Scott J Diede; Stephen J Tapscott
Journal:  Genes Dev       Date:  2009-03-15       Impact factor: 11.361

7.  The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation.

Authors:  Irene Marchesi; Francesco Paolo Fiorentino; Flavio Rizzolio; Antonio Giordano; Luigi Bagella
Journal:  Cell Cycle       Date:  2012-09-14       Impact factor: 4.534

8.  TBX2 blocks myogenesis and promotes proliferation in rhabdomyosarcoma cells.

Authors:  Bo Zhu; Meiling Zhang; Stephanie D Byrum; Alan J Tackett; Judith K Davie
Journal:  Int J Cancer       Date:  2014-01-27       Impact factor: 7.396

9.  RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth.

Authors:  Francesca Riuzzi; Guglielmo Sorci; Rosario Donato
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

10.  Overexpression of the skNAC gene in human rhabdomyosarcoma cells enhances their differentiation potential and inhibits tumor cell growth and spreading.

Authors:  Janine Berkholz; Weronika Kuzyniak; Michael Hoepfner; Barbara Munz
Journal:  Clin Exp Metastasis       Date:  2014-09-11       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.